Advisory Board

The Advisory Board of the Wales Cancer Bank (WCB) superseded a Steering group which was originally convened to oversee the initial establishment of the project and this stakeholder group was instrumental in guiding the Cancer Bank through its initial year of existence. The Steering group consisted of representatives from the National Assembly for Wales, Office of Research and Development (WORD), consultant pathologists, professors of clinical and medical oncology, patient and community health council bodies, the commercially successful Wales Cancer Trials Network and members of the WCB executive group and sub-groups.

The Advisory Board is responsible for ensuring that the WCB complies with NHS governance on ethical and clinical issues and that all relevant legislation is recognised and adhered to, as well as considering the strategic operation of the bank. It receives reports from the sub-groups, it directs operations and reports to the Welsh Assembly Government.

It was recognised that a board made up of a wider spectrum of expertise, to include a majority of members external to Wales, would allow greater transparency and give a wider UK perspective. A number of stakeholder groups were identified and approached for representation, including the WCB funders, the NHS in Wales and the Cancer Services Co-ordinating group in Wales. The newly constituted group met for the first time in January 2008 in the Royal Society in London. Mr Nick Ross, lay representative, chairs the Board.

Full membership of the new Advisory Board and their affiliations are detailed below:

WCB Funders
Professor Jonathan Bisson Welsh Government Director NISCHR
Dr Malcolm Adams Cancer Research Wales Chairman Scientific Committee
Mrs Andrea Hague Velindre NHS Trust Cancer Services lead
pic-angelaHague.jpg

Andrea Hague is the Director of Velindre Cancer Centre, the specialist, non-surgical cancer centre in South East Wales and located in Cardiff.

Andrea received her degree in Banking and Finance from Loughborough University and then commenced a career in banking. After working in banking for a few years Andrea had a career change and joined the NHS. Andrea has over 20 years experience in NHS Management, holding a variety of management positions in different organisations including the specialties of surgery, critical care and more recently oncology at Velindre Cancer Centre. Andrea has a particular interest in service improvement for patients. Andrea is a member of IHM and ILM.

Cardiff University
Professor Dylan Jones Cardiff University Pro-Vice Chancellor, College of Biomedical and Life sciences
NHS in Wales
VACANT    
Cancer Services in Wales
Dr Jane Hanson Cancer National Specialist Advisory Group (NSAG) Wales Head NSAG core team and Lead cancer adviser for Wales
pic-janeHansen.jpg

Dr Hanson has worked in NHS since 1977 spending the first 18 years in cancer research which involved working with leading cancer clinicians and scientists in Cardiff and Swansea, Cambridge and London and included research as part of a European Group. In 1996, following publication of Calman Hine Report on Cancer Services she left research and moved to policy/strategy as Programme Co-ordinator for the Cancer Services Expert Group working with cancer policy leads in the Welsh Office/Assembly Government. She has set up and supports an all Wales multiprofessional advisory structure involving cancer experts and patients from across Wales to advise policy makers and support the 3 regional Cancer Networks. This includes setting standards for cancer services and benchmarking those services via national clinical audit. Wales has been at the forefront of cancer standards development, clinical trials, cancer genetics and cancer information to name just a few areas and it has been rewarding to be part of the various teams that have achieved this.

In 2001 she took on the additional role as Lead Advisor for Cancer and Cancer Services to ensure advice from the clinical advisory groups is communicated to Assembly colleagues in developing policy. In relation to the other home countries, she has established extensive links with clinical leads and policy colleagues in England and Scotland which has enabled good practice in all countries to be recognised and shared.

IT specialist/Health informatics
Dr Jem Rashbass Eastern Cancer Registration and Information Centre Director
Mr Andrew Griffiths NHS Wales Informatics Service Director of Informatics Services
Tissue Banking
VACANT    
Nursing
Mrs Debbie Beirne St James’ hospital Nurse consultant
Bioethicist
Professor Hazel Biggs Southampton University Professor of Healthcare law and Bioethics
pic-hazelBiggs.jpg

Hazel Biggs is Professor of Healthcare Law and Bioethics at the University of Southampton. She received her first degree from the University of Kent after working for several years as a radiographer and ultrasonographer in the National Health Service. Her PhD thesis examined legal and ethical aspects of euthanasia and formed the basis of her first book, Euthanasia, Death with Dignity and the Law (2001). Hazel's research focuses on Healthcare Law and bioethics generally, with particular emphasis on end of life decision-making, human reproduction and the beginning of life, and the ethics and law of clinical research. Alongside her university activities Hazel has chaired local and multi-centre NHS Research Ethics Committees, and recently published a book examining the legal and ethical responsibilities of RECs (Healthcare Research Ethics and Law, Routledge 2010). She is also involved with education and training for members of research ethics committees and the medical research community. She is currently an editor of Medical Law Review and a member of the editorial board of Research Ethics Review.

Oncologist
Professor Robert Leonard Imperial College Lead Cancer Clinician
Pathologist
Professor Gordon Stamp Royal Marsden hospital  
pic-gordonStamp.jpg

Professor Stamp has been Chairman of Histopathology at Hammersmith Hospital since 1997. Since his arrival at the pathology department he has been instrumental in the turnaround of the previously financially underachieving department and has coordinated a successful multidisciplinary research programme (peer reviewed grant income £2.5M 1997 – 2002) in cancer biology and inflammation/immunity, personally supervising 6 PhD students. He has developed the Human Biomaterial Resource Centre (HBRC), a UK/MRC model for Ethical and Clinical Governance issues in human cells and tissue in Research, Teaching and Diagnosis and has specialist pathology expertise in oncological diagnosis with lead roles in skin, gastrointestinal and other cancers. He is a scientific advisor in Pathology to Cancer Research UK and is Chairman of Histopathology Examinations in the Royal College of Pathologists (implementing a radical change in the examination structure to facilitate training and academic development in Histopathology). He has developed internationally recognised specialist training courses in pathology and cancer biology and has written 100 expert reports for legal counsel in the assessment of professional competence in Histopathology. He is the Director of postgraduate training courses in pathology (Hammersmith short courses) and has worked closely with industry. He has a number of active collaborations and has acted as a consultant generating over £2.6M research income for the Department via these interactions, covering the fields of biosourcing, genomics / proteomics and molecular therapeutics/diagnostics. Professor Stamp has authored 162 peer reviewed scientific publications.

Surgeon
Professor Brian Davidson Royal Free hospital Professor of Surgery
pic-brianDavidson.jpg

Brian Davidson is Professor of HPB and Liver Transplant Surgery at UCL and Consultant surgeon and HPB clinical lead at the Royal Free Hospital. Major research interests are in the treatment and pathogenesis of HPB cancers, organ preservation and ischaemia reperfusion injury and novel methods for minimally invasive HPB surgery. He is Editor of the UK Cochrane HPB Group, Director of UCL MSc in Evidence based healthcare. He has published over 380 peer reviewed papers and has a recent grant income over £4M. A recent award as UCL Knowledge Transfer Champion has allowed a programme to be established to facilitate the use of human tissues for research for patient benefit.

Translational scientist
VACANT    
Industry
Dr Rick Greville ABPI Cymru Director
pic-richardGravelle.jpg

Dr Richard Greville is an ABPI Director with Senior Leadership Team responsibility for Wales and International Affairs. He was initially appointed to the post of Director of ABPI Cymru Wales in May 2003 after serving an apprenticeship of 15 years in a wide range of roles within the pharmaceutical industry. In 2007 Richard gained additional responsibility as Director of ABPI Northern Ireland and enjoyed the challenges of raising the understanding and profile of the pharmaceutical industry with a variety of stakeholders, including Assembly policy makers and influencers.

On relinquishing responsibility for Northern Ireland in November 2012, Richard has assumed responsibility for International Affairs, representing the interests of both the ABPI and UK. This includes representing ABPI strategically at both the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), identifying, responding and influencing proposals which may impact on ABPI members. He is also the principle conduit for ABPI engagement with UK Trade & Investment (UKTI), World Trade Organization (WTO) and others on international issues such as Intellectual Property and Trade Bi-laterals. He works alongside UK Life Science and the Department for Business, Innovation & Skills (BIS) to support the Office of Life Sciences inward investment strategy.

He is also a member of the Advisory Boards of the National Institute for Social Care and Health Research, Health Informatics Research Unit (HIRU) at Swansea University and Diabetes Diploma at the University of Glamorgan.

Professor Barry Furr Llangarth Limited  
pic-barryFurr.jpg

Barry Furr is a reproductive biologist and endocrinologist by training who worked for over 33 years at AstraZeneca and its associate companies. He held a range of research management positions, retiring in 2005 as Chief Scientist. He worked on the antioestrogenic breast cancer drug, tamoxifen, and both Zoladex and Casodex for prostate cancer were discovered in his laboratory.

He is a Fellow of the Academy of Medical Sciences and Institute of Biology, and has an honorary chair at the University of Manchester. He is a William Pitt Fellow at Pembroke College, Cambridge and a Trustee of the Breast Cancer Campaign and member of the CRUK Council Research Strategy Committee. He has been Chairman of the Industry Forum of the Academy of Medical Sciences and of the Society of Endocrinology and a council member of the Biosciences Federation.

He was awarded an OBE in 2000 for his contribution to cancer research. He was awarded the Society for Drug Research Prize for Drug Discovery and the Jubilee Medal of the Society for Endocrinology. He is now a consultant for a number of important companies, including, Almac, Evgen, Medivir, Abingworth, SV Life Sciences, MVM, and Astex, and is chairman of Langarth Ltd and a non-executive Director of Genus, GTx and the MHRA.

Business
Professor Barry Furr Llangarth Limited/AstraZeneca Consultant
pic-barryFurr.jpg

Barry Furr is a reproductive biologist and endocrinologist by training who worked for over 33 years at AstraZeneca and its associate companies. He held a range of research management positions, retiring in 2005 as Chief Scientist. He worked on the antioestrogenic breast cancer drug, tamoxifen, and both Zoladex and Casodex for prostate cancer were discovered in his laboratory.

He is a Fellow of the Academy of Medical Sciences and Institute of Biology, and has an honorary chair at the University of Manchester. He is a William Pitt Fellow at Pembroke College, Cambridge and a Trustee of the Breast Cancer Campaign and member of the CRUK Council Research Strategy Committee. He has been Chairman of the Industry Forum of the Academy of Medical Sciences and of the Society of Endocrinology and a council member of the Biosciences Federation.

He was awarded an OBE in 2000 for his contribution to cancer research. He was awarded the Society for Drug Research Prize for Drug Discovery and the Jubilee Medal of the Society for Endocrinology. He is now a consultant for a number of important companies, including, Almac, Evgen, Medivir, Abingworth, SV Life Sciences, MVM, and Astex, and is chairman of Langarth Ltd and a non-executive Director of Genus, GTx and the MHRA.

Lay member
Mr Nick Ross    
pic-nickRoss.jpg

Nick Ross is a broadcaster best known on Radio 4 for current affairs and for TV documentaries, debates and for Crimewatch UK which he presented from its inception in 1984 until 2007. He has served on numerous government inquiries and committees including the Clothier Committee into the ethics of gene therapy, the Gene Therapy Advisory Committee and the NHS Review Team. He has been a member of the Nuffield Council on Bioethics and several other national ethics boards including those for the Royal College of Physicians and the Academy of Medical Sciences inquiry into the use of non-human primates in research. He has twice been chairman of the Royal Society Science Book Prize, a Guest Director of the 2008 Cheltenham Science Festival, and he inspired the Jill Dando Institute of Crime Science at UCL where he is an honorary fellow and visiting professor. He is a director of the UK Stem Cell Foundation and of Sense About Science, is president of HealthWatch, and is chairman, ambassador or patron of around twenty charities.


Sub-groups

Lay Liaison and Ethics group
Chair – Mr Bob Hall
Consists of representatives from patient groups across Wales and originally advised on patient information sheets and consent forms compilation. The group has since expanded to include representation from Community Health Council, PR and fund raising experts. It continues to monitor patient involvement and advises on recruitment procedures from the patient’s perspective and has also recently drafted a communication strategy.
Collection Management group
Chair – Dr Alison Parry-Jones
Consists of the IT Manager and the nurses and technicians employed in local hospitals. All aspects of the day to day collection are monitored and this group helps to foster team collaboration as the project is geographically spread across Wales.
IT re-write project board
Chair
Responsible for overviewing the central database system and forward planning of system updates in conjunction with the IT Manager and liaison with existing information services groups with the aim to fully integrate the Cancer Bank database on an all Wales basis.
Sampling group
Consists of pathologists and technical staff and was initially responsible for the collation of sample collection protocols and standard operating procedures.